CMS Lacks Authority To Include "Authorized" Generic In A Brand's "Best Price"
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Secretary Leavitt suggests the agency cannot dictate that the "best price" of an "authorized" generic be included in the Medicaid rebate calculation for the brand drug. The position appears to be a blow for the generic industry, which is seeking to change rebate reporting requirements for brand drugs with authorized generics.
You may also be interested in...
“Authorized” Generic Could Be Added To Brand’s “Best Price,” HHS Clarifies
HHS assures Sen. Schumer (D-N.Y.) that administrative revision of “best price” reporting requirements is possible, provided the Centers for Medicare & Medicaid Services follows formal rulemaking procedures.
“Authorized” Generic Could Be Added To Brand’s “Best Price,” HHS Clarifies
HHS assures Sen. Schumer (D-N.Y.) that administrative revision of “best price” reporting requirements is possible, provided the Centers for Medicare & Medicaid Services follows formal rulemaking procedures.
CMS Offers “Quickest Fix” To “Authorized” Generics, CEO Coury Says
The Centers for Medicare & Medicaid Services could provide the "quickest fix" for the generic industry's complaints about "authorized" generics, Mylan CEO Robert Coury said Feb. 3